1、novotech-June 10,2024Chronic Lymphocytic LeukemiaGlobal Clinical Trial Landscape(2024)The Asia-Pacific region shows shorter recruitment durations as compared to the United StatesCLL is a slow growing Leukemia character-ized by progressive accumula-tion of dysfunctional monoclonal B lymphocytesMarket

2、ed drugs include Imbruvica(ibrutinib)targeting Brutons tyrosine kinase(Btk),and monoclonal antibodies like Zytux(biosimilar rituximab)targeting CD20Phase III pipeline drugs,such as nemtabrutinib targeting Btk,and U2 targeting CD20 and PI3K,signify promising advance-ments in CLL treatmentThe content

3、of this publication is proprietary to Novotech Health Holdings.No part of this publication may be reproduced,distributed,or transmitted in any form or by any means,including photocopying,recording,or other electronic or mechanical methods,without the prior written permission of Novotech except in th

4、e case of quotations embodied in reviews and non-commercial uses.Please note that this copyright statement applies specifically to this publication and its content and does not extend to other materials or intellectual property owned by Novotech.Any unauthorized reproduction or distribution of this

5、publication or any portion thereof may result in legal action taken by Novotech to protect its rights.For permissions or inquiries,please contact:communicationsnovotech-#DYK Did youknow?The United States estimated the highest number of CLL cases in North AmericaIn Europe,Germany estimated a relative

6、ly higher incidence of CLLIn the Asia-Pacific region,China estimated a relatively higher incidence of CLL casesIn ROW,Brazil reported the highest incidence of CLL10%ROW55%NORTH AMERICA&EUROPE35%ASIA-PACIFICIn 2022,there were an estimated 121,000 cases of CLLTRIAL CONTRIBUTIONSCHRONIC LYMPHOCYTIC LEU